Compass Pathways CEO on Trump's Order to Expand Psychedelics Research

Shares of psychedelic-therapy names surged after President Trump signed an executive order aimed at expediting research and access, with Compass Pathways up as much as 53%, AtaiBeckley up 37%, GH Research up 34%, and Definium Therapeutics up 16%. The FDA is now directed to issue expedited review vouchers for breakthrough-designation psychedelics, cutting review times to one to two months from six to ten months. The AdvisorShares Psychedelics ETF (PSIL) rose as much as 20%, reaching its highest intraday level since July 2023.

Analysis

The immediate winners are the names with actual breakthrough designations, but the bigger second-order effect is that regulatory optionality just got repriced across the entire experimental mental-health pipeline. A one- to two-month review window materially compresses the financing overhang for small-cap biotech: it lowers the probability of a dilutive raise before a decision and increases the value of any near-term catalyst, which is why the move is likely to persist beyond a one-day headline reaction if the FDA operationalizes this quickly.

CMPS still looks best positioned on a relative basis because it combines the strongest policy torque with the clearest institutional use-case: a faster path to an FDA decision improves the odds of strategic interest from larger pharma or specialty mental-health players looking for de-risked assets. ATAI’s broader platform means more upside if sentiment spills into earlier-stage programs, but that also makes it harder to underwrite as a pure policy winner; GHRS is more vulnerable to the market realizing this is a rerating of regulatory timing, not a blanket approval of the space.

The key risk is that the market is extrapolating speed to approval when the order only improves process, not clinical probability. If the FDA uses the voucher selectively or requests additional data anyway, the trade can fade quickly over the next 2-6 weeks. A deeper risk is positioning: after a 30-50% gap move, crowded retail and event-driven longs create a sharp air-pocket if Washington follow-through is slower than headline optics.

Contrarian take: the strongest relative trade may be selling strength in the least differentiated name rather than chasing the whole basket. The policy is most valuable where commercialization is closest, so the market may be overpaying for beta exposure via the ETF while underpricing dispersion between a truly designated asset and the rest of the group. That argues for selective longs, not indiscriminate exposure to the theme.

Key Decisions for Investors

• Long CMPS vs short PSIL for 2-6 weeks: express the view that policy benefits accrue disproportionately to the highest-quality, breakthrough-designated asset rather than the basket; target a further 10-15% relative outperformance with lower downside than outright beta.
• Buy ATAI only on a pullback over the next 3-5 sessions: use weakness to build a smaller position, since the upside is real but the platform story is less clean; risk/reward improves if the post-gap retrace holds above the pre-news breakout level.
• Avoid chasing GHRS at current levels; if you want theme exposure, prefer a defined-risk call spread over outright equity for the next 1-2 months, because GHRS is most exposed to a 'process, not approval' reversion.
• For event-driven accounts, sell near-dated covered calls on CMPS after the opening volatility settles; the implied move is likely overstating incremental policy upside, and call premium can monetize the crowded flow.
• Set a catalyst watch for FDA implementation language over the next 2-4 weeks: if the agency clarifies fast-track mechanics, add to CMPS/ATAI; if guidance is vague or restrictive, fade the basket and rotate out of PSIL.